Chandigarh: ICMR chief lauds institute's innovation, 31 workers honoured
Dr Rajiv Bahl, secretary to the government of India in the department of health research and the director general of the Indian Council of Medical Research, was the chief guest at the 62nd Foundation Day event. A total of 31 PGIMER employees were felicitated for their outstanding service to the institution.
Applauding PGIMER's achievements, Dr Bahl said, 'PGI's leadership in clinical trials and research is crucial for India's future in global healthcare innovation.'
Founded in 1962 and inaugurated on July 7, 1963, PGIMER was declared an Institute of National Importance in 1967. Spread across 277 acres, the institute today has over 11,800 staff, including 728 faculty members and 1,300 resident doctors. It has a capacity of 2,233 beds, with 207 ICU beds and 73 operation theatres, catering to nearly 10,000 outpatients daily.
'Devices like the infrared hematoma detector and Mobi-lab, developed with ICMR support, have attracted international attention—even from Bill Gates,' said Dr Bahl.
Dr D Behera, PGIMER's professor emeritus and president, National Academy of Medical Sciences, attended the event as guest of honour.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
4 hours ago
- Time of India
Not always simple: Doctors flag hidden risks of bronchoscopy procedures in Bengaluru
Bengaluru: While bronchoscopy is often described as a minimally invasive tool to diagnose or treat respiratory illnesses, doctors warn that the procedure carries significant risks — ranging from severe bleeding and airway blockages to lung collapse. At the Conclave of Advanced Pulmonary Interventions (CAPI-2025) organised by Dr Ravindra Mehta, director of Vaayu Chest and Sleep Specialists, Dr Sahajal Dhooria, professor of Pulmonary Medicine at PGIMER, Chandigarh, said: "A little bit of bleeding is expected, especially during tissue biopsies. But it becomes a complication when the bleeding is moderate or massive, interfering with organ function," Airway obstruction is another critical risk. Dr A Jayachandra, senior interventional pulmonologist at Care Hospitals, Hyderabad, said a tumour being removed from one airway could roll over and block another. "You then end up compromising two air passages," he said. You Can Also Check: Bengaluru AQI | Weather in Bengaluru | Bank Holidays in Bengaluru | Public Holidays in Bengaluru A collapsed lung, or pneumothorax, may also occur if air leaks into the chest cavity during a biopsy or needle-based intervention. "It's like a punctured balloon. The lung can't expand unless you stop the leak," said Dr Dhooria. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Interested in Investing? Cyprus Offers Many Options Cyprus Invest | Search ads Undo Given the risks, careful patient selection and practitioner self-awareness are crucial, said Dr Pyng Lee, director of Interventional Pulmonology at Singapore's National University Hospital. "Do not let ego come in the way. If someone else is more experienced, let them take over. That saves lives," she said. Doctors also highlighted the importance of normalising open conversations around complications — still rare in India's clinical ecosystem. "Most of this is still shared only in close circles. There's a fear of being seen as incompetent, or legal issues arising. But everyone faces complications," Dr Jayachandra said. Dr Mehta said acknowledging and sharing such outcomes helps build a stronger safety culture. "We need more forums like this. That's how we improve care," he said. Sometimes, doctors face bizarre cases of foreign objects lodged in patients' airways. Dr Karan Madan of AIIMS, New Delhi, once treated a fisherman who held a fish in his mouth only for it to slip into his windpipe. Dr David Fielding, a thoracic physician from Australia, recounted having to remove peanuts people had inhaled during party tricks, and even teeth lost in accidents. While children under three remain the most vulnerable to inhaling small objects, doctors advise against trying to forcibly remove them from a child's mouth. "Crying increases air intake, which can suck the object deeper into the airway," said Dr Jayachandra. Box City hosts 1st silent summit for eye specialists In a break from the usual buzz of medical conferences, 450 ophthalmologists sat in near silence at a city hotel Sunday, attending what was billed as Bengaluru's first Silent Summit for the medical community. Organised by the Bangalore Ophthalmic Society (BOS), the unique format replaced conventional multiple-hall sessions with a single room, four-panel discussions running simultaneously, and headphones for each delegate. Instead of dashing between halls, participants tuned in to sessions of their choice by switching channels on their headsets. "It allowed seamless access to all tracks without moving around," said Dr Elankumaran P, BOS president. The conference screen was split into four sections for each ongoing panel, and mics were placed in front of each lane for audience interaction. Inspired by multilingual events like those at the United Nations and European medical conferences, the format cost BOS an additional Rs 10 lakh in tech — but saved on venue rentals. The system supported up to 40 channels and was previously used in ophthalmology summits in Haryana and Barcelona. Despite the success, nine headphones went missing by the end of the event, organisers said. | TNN
The Hindu
13 hours ago
- The Hindu
ICMR study finds only 28.5% of cancer patients receive radiotherapy in India
Radiotherapy is a cornerstone of cancer treatment in India, yet its expansion is hindered by high investment costs and effective planning, target estimation based on cancer burden are crucial to meet the radiotherapy demands of patients with cancer, noted a recent Indian Council for Medical Research (ICMR) study published in the UK-based BioMed Central (BMC) cancer journal early this month. Major shortfall in radiotherapy access India is faced with a substantial shortfall in radiotherapy utilisation across all cancer types and 28.5 percent of cancer patients receive radiotherapy, which is lower than the estimated optimal rate of 58.4 per cent. Breast, head and neck, lung and cervical cancer account for 60 per cent of India's radiotherapy needs. This underscores the need for interventions to meet the gap in machines required for equitable cancer care,'' said the study. Data from the Australian Collaboration for Cancer Outcomes Research and Evaluation (CCORE) were used by the researchers of ICMR-National Centre for Disease Informatics and Research, Bengaluru, for conducting the study. India accounts for 7 per cent of global cancer incidence, ranking third after China and the USA. By the end of 2025, the incidence of cancer in India is projected to reach 1.57 million cases, posing a significant public health challenge. Cancer burden in India As the fifth leading cause of death in the country, cancer demands urgent attention to improve prevention, diagnosis and treatment. Epidemiological data on stage, subsite and histology from the National Cancer Registry Programme were used to assess the optimal utilisation proportion for India. A sensitivity analysis was carried out. Similarly, the optimal radiotherapy fraction has also been calculated. These measures have been used to estimate the existing radiotherapy utilisation gap by comparing with the current radiotherapy utilisation from the cancer registry as well as to estimate the optimal radiotherapy machines required for the country. This study provides a comprehensive assessment of radiotherapy demand and existing gaps in radiotherapy utilisation and in the number of machines in India based on an epidemiological analysis of the cancer burden from the National Cancer Registry Programme. The study also recommended that India would require 1,585 to 2,545 machines, which may increase to a range of 2,016 to 2,291 external beam radiotherapy machines if the assumptions from previous benchmark studies are followed. This points towards an increasing demand for radiotherapy in the coming years as there is expected to be a 70-100 per cent increase in breast, head and neck and lung cancer in low and middle income countries (LMIC). Among the major indicated cancer sites, the deficit is more prominent in lymphoma and lung cancer (relative deficit of more than 70 per cent), followed by prostate, breast and oesophagus, said the study adding that radiotherapy, plays a crucial role in controlling tumour growth, reducing tumour size pre-surgery, and alleviating pain in advanced stages. Stating that high setup and operational costs are creating a significant gap between demand and resources, the study states that there is a need for greater investment to expand radiotherapy facilities to meet the growing demands of cancer patients. Urgent need to expand machines and reduce inequities The World Health Organization (WHO) recommends a minimum of one radiotherapy machine (external radiotherapy machine) per million population, with an optimal target of four per million, the study stated. For India's projected population of 1.45 billion in 2025, this translates to a need for a minimum of 1,450 machines. Yet, only 794 megavoltage (MV) machines are currently available. The shortfall is about 45 per cent from the minimal required standard, the study said. It further notes that aside from increasing the number of equipment, addressing the inequitable distribution of radiotherapy services is also crucial. To align with the country's cancer burden and ongoing control efforts, India must meet evidence-based targets for radiotherapy machine availability. The country is also ramping up efforts to develop and deploy affordable indigenous radiotherapy machines to improve access and reduce dependence on costly imports,' the study stated. The study notes that there is need for detailed situational study of radiation equipment deployment with its features and complexity, utilisation and throughput is required for informed planning and policymaking. Cancer screening and early detection programmes can facilitate the diagnosis of cancers at earlier stages. This could reduce the required quantum of radiotherapy shortly and thus, improve the overall survival of patients, the study said.
Indian Express
21 hours ago
- Indian Express
Knowledge Nugget: AdFalciVax and the fight against malaria — What you must-know for UPSC Exam
Take a look at the essential events, concepts, terms, quotes, or phenomena every day and brush up your knowledge. Here's your UPSC Current Affairs Knowledge Nugget for today on AdFalciVax and malaria. The Indian Council of Medical Research (ICMR) has invited the country's vaccine manufacturers to partner with it to launch and sell a malaria vaccine, AdFalciVax, that its Regional Medical Research Centre, Bhubaneshwar, has developed. In this context, let's know about this new vaccine and malaria. 1. AdFalciVax is a chimeric recombinant vaccine — a type of vaccine that uses different parts of the genes of a pathogen (in this case, Plasmodium) to create target proteins that trigger an immune response after being injected. 2. AdFalciVax uses two types of target proteins to prevent the spread of infection in two different ways. ↪ It uses the circumsporozoite protein (CSP) to prevent infection in the person who has been immunised. The CSP is produced during the sporozoite stage (when a parasite can infect a new host) and the liver stage (when a parasite enters liver cells, multiplies, and then infects red blood cells) of the parasite. 'Any immune response generated against these stages protects the immunised person from getting the infection.' Subhash Singh, project manager for development of the vaccine at the ICMR-Regional Medical Research Centre, Bhubaneswar told The Indian Express. ↪ The vaccine also uses the Pro6C protein, a fusion of parts of two different proteins — Pfs230 and Pfs48/45 — produced by Plasmodium falciparum. This protein prevents the spread of infection in the community. 3. Researchers have found that AdFalciVax provided more than 90% protection against infection in mice. The candidate vaccine has yet to undergo rigorous human trials, and the preliminary results have been obtained only through testing on animals. 4. The ICMR wants to partner with a company that can further develop its candidate vaccine, carry out human clinical trials, and scale up for commercial production. Although the ICMR will share the technology of developing AdFalciVax with the chosen company, it will continue to hold the intellectual property rights. Any intellectual property rights generated during the collaboration will be held jointly by the ICMR and the company. 5. Notably, AdFalciVax mainly targets two parts of Plasmodium falciparum, a pathogen that is the most common source of malaria in humans. In India, however, the disease is caused by Plasmodium vivax against which AdFalciVax is ineffective. To combat malaria, scientists have been working to develop a vaccine for decades but with limited success. Recently, two vaccines—RTS,S and R21—were approved for use, but their efficacy, at 75%, is quite low. That's why the announcement about ICMR's candidate vaccine has given new hope in the fight against the disease. World Malaria Day is observed every year on 25th April by the World Health Organisation to raise awareness and drive action against malaria. The theme for World Malaria Day 2025 is 'Malaria Ends With Us: Reinvest, Reimagine, Reignite.' 1. Having claimed millions of lives, malaria has been one of the deadliest diseases in human history. Currently, the disease kills about four lakh people annually, according to World Health Organization (WHO) figures. 2. Malaria is a parasitic infection transmitted by mosquitoes, typically causing symptoms such as fever, chills, night sweats, nausea, vomiting, and diarrhoea. In some cases, it can lead to severe complications such as seizures, fluid in the lungs, organ damage, and death. 3. It is most endemic in Africa — Nigeria, Congo, Tanzania, Mozambique, Niger, and Burkina Faso together account for more than half the yearly deaths. 1. India has demonstrated significant progress in reducing malaria cases and associated mortality in the country's high-endemic states, according to the findings of the World Health Organisation's (WHO) 'World Malaria Report 2024′. 2. 'India exited the HBHI [high-burden to high-impact] group officially in 2024 due to significant progress in reducing the malaria incidence and mortality observed in its high-endemic states,' the report observed. 3.'Nationwide, the number of estimated malaria cases in India decreased from 6.4 million in 2017 (the year before the HBHI's introduction) to 2 million cases in 2023 (69 per cent decrease). Similarly, the estimated malaria deaths decreased from 11,100 to 3,500 (68 per cent decrease) during the same period,' it said. 4. The HBHI refers to a targeted WHO initiative aimed at the most acutely malaria-impacted regions of the world, including several countries in Africa. Widespread resistance of malarial parasite to drugs like chloroquine has prompted attempts to develop a malarial vaccine to combat malaria. Why is it difficult to develop an effective malaria vaccine? (UPSC CSE 2010) (a) Malaria is caused by several species of Plasmodium (b) Man does not develop immunity to malaria during natural infection (c) Vaccines can be developed only against bacteria (d) Man is only an intermediate host and not the definitive host (Sources: India registers 'significant progress' in reducing malaria cases: WHO, WHO report says India reduces malaria caseload, deaths by 69% each) Subscribe to our UPSC newsletter. Stay updated with the latest UPSC articles by joining our Telegram channel – Indian Express UPSC Hub, and follow us on Instagram and X. 🚨 Click Here to read the UPSC Essentials magazine for July 2025. Share your views and suggestions in the comment box or at
